We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

GC Labs Highlight Its “Smart Lab” Concept at MEDLAB Middle East 2022

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Image: GC Labs Highlight Its `Smart Lab` Concept at MEDLAB Middle East 2022  (Photo courtesy of GC Labs)
Image: GC Labs Highlight Its `Smart Lab` Concept at MEDLAB Middle East 2022 (Photo courtesy of GC Labs)

GC Labs (Yongin, South Korea) participated in the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27 where it offered a ‘smart experience’ for visitors to learn more about the diagnostic services offered by the company.

At the event, GC Labs highlighted its “smart lab” concept that provides an automated test system to improve speed and efficiency of tests, allowing the company to report results in just a day or two. The increase in demand for genetics and infectious disease tests in the region has prompted GC Labs to plan further expansion in the Middle East. Currently offering their services in Saudi Arabia and the UAE, the company is in talks with regional partners to expand their services to more countries in the Middle East. More than 800 employees at GC Labs offer over 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays.

GC Labs hosted its seminar on ‘Public-Private Partnership in Global Health: bringing the best of both worlds to improve testing’ on January 25 at the Bubble Lounge in Medlab. The seminar had an impressive line-up of speakers with globally renowned specialists including Lelio Marmora, former CEO in Unitaid; Michel Kazatchkine, former executive director the Global Fund to Fight AIDS, TB and Malaria; Dr Eskild Petersen, MD, Editor-in-chief of IJID Regions, an official journal of the International Society for Infectious Diseases (ISID); Dr Amina Al-Jardani, Director of Central Public Health Laboratories (CPHL), Directorate General for Disease Surveillance and Control, Ministry of Health, Oman; and Lee. The seminar was an interactive session with an opportunity for attendees to ask questions.

“The Middle East is an important market for us, and participating in MEDLAB will help us to share our best practices in clinical diagnostics with the regional health community. Over the past two decades, the world has achieved important success in the fight against pandemics like COVID-19 and in mobilizing global response against HIV-Aids, TB, Malaria and other infectious diseases,” said Eun-Hee Lee, President at GC Labs. “Medical laboratories play a key role in this fight by providing high quality diagnostic testing and by working in partnership with the health authorities. To highlight the importance of private and public partnership in the fight against infectious diseases and pandemics, we are organizing a seminar during MEDLAB to bring together international experts to share their own experiences and expertise, focus on lessons learned, and discuss how to best manage public and private partnerships to successfully fight against pandemics and infectious diseases in the future.”

Related Links:
GC Labs 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
pHOx Analyzer
BioProfile pHOx Analyzer
Gold Supplier
Human Chorionic Gonadotropin (hCG) Test
OSOM hCG Combo Test
Auto Biochemistry & Turbidimetry Analyzer
Labmax 400

Print article


Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.